Otofarma reports 12.5% production increase for H1 2026

Otofarma, a company listed on Euronext Growth Milan specializing in the hearing care sector, has released its financial results for the first half of 2026.

The company reported production value of 9.6 million euros, representing a 12.5% increase compared to the 8.53 million euros recorded during the same period in 2025. However, the net result for the period was negative at 519,000 euros, compared to a pro forma loss of 177,000 euros in the first half of 2025.

As of late June 2026, the net financial position stood at 5.03 million euros, down from 7.09 million euros at the start of the year. This decrease is attributed primarily to investments made to support the evolution of the group's commercial and distributive organization. For the second half of 2026, Otofarma intends to continue its growth path by focusing on the value of these recent investments.